# RINVOQ® (upadacitinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/upadacitinib

> The FDA approved RINVOQ® (upadacitinib), sponsored by AbbVie Inc. (ABBV), on July 31, 2025 for with giant cell arteritis.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | RINVOQ® (upadacitinib) |
| Codes | ABT-494 |
| Sponsor | AbbVie Inc. (ABBV) https://sec-api.dev/companies/abbv/catalysts |
| Indications | with moderately to severely active ulcerative colitis, with giant cell arteritis, [Crohn's Disease](https://sec-api.dev/indications/crohn-s-disease), [Alopecia Areata](https://sec-api.dev/indications/alopecia-areata), [Atopic Dermatitis](https://sec-api.dev/indications/atopic-dermatitis), [Systemic Lupus Erythematosus](https://sec-api.dev/indications/systemic-lupus-erythematosus), [Juvenile Idiopathic Arthritis](https://sec-api.dev/indications/juvenile-idiopathic-arthritis), [Takayasu Arteritis (TAK)](https://sec-api.dev/indications/takayasu-arteritis-tak) |
| Modality | small_molecule |
| FDA designations | priority review |

## Timeline

### August 16, 2019: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211675 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20190816, review_priority PRIORITY; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22

### December 14, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211675 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20211214, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22

### January 14, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211675 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20220114, review_priority PRIORITY; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22

### March 16, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211675 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20220316, review_priority PRIORITY; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22

### April 29, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211675 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20220429, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22

### October 21, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211675 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20221021, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22

### May 18, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211675 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20230518, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22

### June 22, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211675 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20230622, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22

### April 26, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA218347 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20240426, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ LQ (UPADACITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218347%22

### April 26, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211675 SUPPL-22 (Efficacy): submission_status AP, submission_status_date 20240426, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22
- openFDA Drugs@FDA: "NDA211675 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20240426, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22

### April 28, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211675 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20250428, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22

### July 18, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Crohn's Disease (CD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02782663 (A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-18 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-08-13." https://clinicaltrials.gov/study/NCT02782663

### July 31, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: with giant cell arteritis.
- First seen 2025-07-31, last confirmed 2025-07-31.
- Press release filed with the SEC (EX-99) (accession 0001551152-25-000036): "•AbbVie announced the U.S. Food and Drug Administration (FDA) approved Rinvoq (upadacitinib) as the first oral Janus Kinase (JAK) inhibitor approved for the treatment of adults with giant cell arteritis (GCA)." https://www.sec.gov/Archives/edgar/data/1551152/000155115225000036/abbv-20250630xexhibit991.htm

### October 10, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211675 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20251010, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22

### October 31, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact. Indication: with moderately to severely active ulcerative colitis.
- First seen 2025-10-31, last confirmed 2025-10-31.
- Press release filed with the SEC (EX-99) (accession 0001551152-25-000047): "•AbbVie announced the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) that updates the indication statement for Rinvoq (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD)." https://www.sec.gov/Archives/edgar/data/1551152/000155115225000047/abbv-20250930xexhibit991.htm

### July 15, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Rheumatoid Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05814627 (Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-15 (ACTUAL); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT05814627

### August 13, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2. Indication: Crohn's Disease (CD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02782663 (A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-18 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-08-13." https://clinicaltrials.gov/study/NCT02782663?tab=results

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Atopic Dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06389136 (A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06389136

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Atopic Dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06389136 (A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06389136

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Atopic Dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06701331 (Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06701331

### Jan to Apr 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Atopic Dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06701331 (Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06701331

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Systemic Lupus Erythematosus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05843643 (Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT05843643

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Systemic Lupus Erythematosus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05843643 (Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT05843643

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03345823 (A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT03345823

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03345823 (A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT03345823

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Vitiligo.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06118411 (A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06118411

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Vitiligo.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06118411 (A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06118411

### August 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Takayasu Arteritis (TAK).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04161898 (A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT04161898

### Aug to Nov 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Takayasu Arteritis (TAK).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04161898 (A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT04161898

### August 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05782907 (Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT05782907

### Aug to Nov 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05782907 (Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT05782907

### August 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Hidradenitis Suppurativa.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05889182 (A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT05889182

### Aug to Nov 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Hidradenitis Suppurativa.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05889182 (A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT05889182

### February 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Alopecia Areata.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07023302 (A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-02 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT07023302

### Feb to May 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Alopecia Areata.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07023302 (A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-02 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT07023302

### June 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Juvenile Idiopathic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05609630 (Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT05609630

### Jun to Sep 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Juvenile Idiopathic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05609630 (Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT05609630

### July 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Rheumatoid Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07904754 (Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT07904754

### Jul to Oct 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Rheumatoid Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07904754 (Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT07904754

### November 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Atopic Dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06461897 (A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-11 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06461897

### Nov 2029 to Feb 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Atopic Dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06461897 (A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-11 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06461897

### April 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Alopecia Areata.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06012240 (A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06012240

### Apr to Jul 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Alopecia Areata.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06012240 (A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06012240

## Same indication

- [ABBV-8736](https://sec-api.dev/pdufa/abbv-8736) (ABBV)
- [Cibinqo (abrocitinib)](https://sec-api.dev/pdufa/abrocitinib) (PFE)
- [Amlitelimab](https://sec-api.dev/pdufa/amlitelimab) (SNY)
- [Saphnelo (anifrolumab)](https://sec-api.dev/pdufa/anifrolumab) (AZN)
- [Anifrolumab + apfs](https://sec-api.dev/pdufa/anifrolumab-apfs) (AZN)
- [ATI-045](https://sec-api.dev/pdufa/ati-045) (ACRS)
- [AZD7798](https://sec-api.dev/pdufa/azd7798) (AZN)
- [Barzolvolimab](https://sec-api.dev/pdufa/barzolvolimab) (CLDX)
- [Bempikibart (adx-914)](https://sec-api.dev/pdufa/bempikibart-adx-914) (QTTB)
- [BLINCYTO® (blinatumomab)](https://sec-api.dev/pdufa/blinatumomab) (AMGN)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Cadefrecitinib](https://sec-api.dev/pdufa/cadefrecitinib) (LKFT)
- [Darvadstrocel](https://sec-api.dev/pdufa/darvadstrocel) (TAK)
- [Sotyktu (deucravacitinib)](https://sec-api.dev/pdufa/deucravacitinib) (BMY)
- [Duvakitug](https://sec-api.dev/pdufa/duvakitug) (SNY)
- [Evo756, dose 1](https://sec-api.dev/pdufa/evo756) (EVMN)
- [GHZ339](https://sec-api.dev/pdufa/ghz339) (NVS)
- [GIA632](https://sec-api.dev/pdufa/gia632) (NVS)
- [Tremfya (guselkumab)](https://sec-api.dev/pdufa/guselkumab) (JNJ)
- [Ianalumab](https://sec-api.dev/pdufa/ianalumab) (NVS)
- [Iv tulisokibart](https://sec-api.dev/pdufa/iv-tulisokibart) (MRK)
- [KT-621](https://sec-api.dev/pdufa/kt-621) (KYMR)
- [Lebrikizumab](https://sec-api.dev/pdufa/lebrikizumab) (LLY)
- [Lutikizumab](https://sec-api.dev/pdufa/lutikizumab) (ABBV)
- [LY4005130](https://sec-api.dev/pdufa/ly4005130) (LLY)
- [MEDI-546](https://sec-api.dev/pdufa/medi-546) (AZN)
- [Mirikizumab](https://sec-api.dev/pdufa/mirikizumab) (LLY)
- [MK-6194](https://sec-api.dev/pdufa/mk-6194) (MRK)
- [Obexelimab](https://sec-api.dev/pdufa/obexelimab) (ZBIO)
- [Pf-07275315 dose 1](https://sec-api.dev/pdufa/pf-07275315) (PFE)
- [PF-08049820](https://sec-api.dev/pdufa/pf-08049820) (PFE)
- [Rezpegaldesleukin](https://sec-api.dev/pdufa/rezpegaldesleukin) (NKTR)
- [Skyrizi® (risankizumab)](https://sec-api.dev/pdufa/risankizumab) (ABBV)
- [Risankizumab iv](https://sec-api.dev/pdufa/risankizumab-iv) (ABBV)
- [Risankizumab sc](https://sec-api.dev/pdufa/risankizumab-sc) (ABBV)
- [Litfulo (ritlecitinib tosylate)](https://sec-api.dev/pdufa/ritlecitinib) (PFE)
- [Rocatinlimab](https://sec-api.dev/pdufa/rocatinlimab) (AMGN)
- [Roflumilast cream 0.3%](https://sec-api.dev/pdufa/roflumilast-cream-0-3) (ARQT)
- [JAKAFI (ruxolitinib)](https://sec-api.dev/pdufa/ruxolitinib) (INCY)
- [Ruxolitinib cream](https://sec-api.dev/pdufa/ruxolitinib-cream) (INCY)
- [Sar441344 iv](https://sec-api.dev/pdufa/sar441344-iv) (SNY)
- [SAR441566](https://sec-api.dev/pdufa/sar441566) (SNY)
- [Sar444656 (kt-474)](https://sec-api.dev/pdufa/sar444656-kt-474) (SNY)
- [Sarilumab sar153191 (regn88)](https://sec-api.dev/pdufa/sarilumab-sar153191-regn88) (SNY)
- [Tapinarof cream, 1%](https://sec-api.dev/pdufa/tapinarof-cream-1) (OGN)
- [Tilrekimig](https://sec-api.dev/pdufa/tilrekimig) (PFE)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)
- [Entyvio® (vedolizumab)](https://sec-api.dev/pdufa/vedolizumab) (TAK)
- [Vedolizumab iv](https://sec-api.dev/pdufa/vedolizumab-iv) (TAK)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/upadacitinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "RINVOQ® (upadacitinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/upadacitinib

```bibtex
@misc{secapidev_pdufa_upadacitinib_20261116,
  title        = {RINVOQ® (upadacitinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/upadacitinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_upadacitinib_20261116","title":"RINVOQ® (upadacitinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/upadacitinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
